Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol - Chiesi Farmaceutici

Next Previous
Drug Profile

Beclometasone/formoterol - Chiesi Farmaceutici

Alternative Names: BDP/FF - Chiesi Farmaceutici; Beclometasone dipropionate/formoterol fumarate dihydrate; Beclomethasone/formoterol; CHF 1535 35/4 NEXTHALER®; CHF-1535; Combair; Formodual; Formoterol/beclometasone; Fostair; Fostair NEXThaler; Foster; Foster Nexthaler; Foster Spray; Fostex; Fostex NEXThaler; Innovair; Innovair NEXThaler; Inuvair; Inuver; Inuxair; Kantos; Kantos Master; Kantos NEXThaler

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Chlorinated steroids; Corticosteroids; Ethanolamines; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 23 Apr 2026 Chiesi Farmaceutici plans a phase III TRICHECO trial for Asthama (Treatment-experienced) in China in May 2026 (Inhalation) (NCT07546981)
  • 04 Feb 2026 Phase III development in Chronic obstructive pulmonary disease is still ongoing in Bulgaria, Hungary, Poland and USA (Inhalation) (NCT04320342)
  • 12 Jan 2026 Chiesi Farmaceutici SpA completes the phase III clinical trials in Chronic obstructive pulmonary disease in Argentina, Bulgaria, Canada, Czechia, Hungary, Mexico, Poland, Puerto Rico, Romania and USA (Inhalation) (NCT04320342)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top